StemCell Therapy

Dublin, April 24, 2020 (GLOBE NEWSWIRE) -- The "North America Cell Expansion Market to 2027 - Regional Analysis and Forecasts by Product; Cell Type; Application; End User, and Country" report has been added to ResearchAndMarkets.com's offering.

The cell expansion market in North America is anticipated to reach USD 14,697.41 million by 2027 from USD 4,522.07 4 million in 2019; it is projected to grow at a CAGR of 15.9% during 2020-2027. The growth of the market is attributed to the increasing prevalence of cancer, rising number of new product launches, and increasing inclination of patients toward regenerative and personalized medicines. Also, growing R&D expenditure on cancer research is likely to have a positive impact on the growth of the market in the coming years. In addition, technological advancements in the pharmaceuticals industry and extensive developments in drug discovery are likely to stimulate the growth of cell expansion market in North America during the forecast period.

Cell expansion is the large-scale artificial production of daughter cells from a single cell, and the process is carried out to support the medical research. It plays a critical role in exploring a wider range of benefits and applications of fully differentiated stem cell cultures for their use in therapeutics, drug screening, or advanced research.

R&D is a significant part of a majority of pharmaceutical and biotech companies; they focus on R&D to come up with new molecules with the most significant medical and commercial potential for various therapeutic applications. The companies invest big amounts in these activities to deliver innovative, high-quality products to the market. Moreover, as per the report of Pharmaceutical Research and Manufacturers of America (PhRMA), the R&D expense of biopharmaceutical companies surged from US$ 49.6 billion in 2012 to US$ 58.8 billion in 2015.

Several government organizations are working on enhancing the detection methods and treatment procedures of cancer in the region. The National Cancer Institute (NCI) spends on various categories of the treatment, including specific cancer sites, cancer types, and cancer-related diseases, as well as types of NCI research mechanisms. The NCI allocated the funds of ~US$ 208.4 million for cell expansion research in 2017 from their total budget of US$ 5,636.4 million in that year for cancer research studies. Therefore, the growing R&D expenditure on cancer research by these companies is expected to provide them with opportunities for business expansion.

The North American cell expansion market has been segmented on the basis of cell type into human cells and animal cells. The human cells segment held a larger share of the market in 2018, and it is also projected to register a higher CAGR in it during the forecast period. Rise in research activities for the treatment of cancer is expected to offer considerable growth opportunities for the human cell expansion market players.

A few of the important secondary sources referred to for preparing this report on the cell expansion market are World Health Organization (WHO), Food and Drug Administration (FDA), Canadian Cancer Society, Centers for Disease Control and Prevention (CDC), and American Cancer Society.

Reasons to Buy:

Key Topics Covered:

1. Introduction1.1 Scope of the Study1.2 Report Guidance1.3 Market Segmentation1.3.1 North America Cell Expansion Market - By Product1.3.2 North America Cell Expansion Market - By Cell Type1.3.3 North America Cell Expansion Market - By Application1.3.4 North America Cell Expansion Market - By End User1.3.5 North America Cell Expansion Market - By Country

2. North America Cell Expansion Market- Key Takeaways

3. Research Methodology3.1 Coverage3.2 Secondary Research3.3 Primary Research

4. North America Cell Expansion Market - Market Landscape4.1 Overview4.2 PEST Analysis4.2.1 Cell Expansion Market - North America PEST Analysis4.3 Expert Opinion

5. North America Cell Expansion Market - Key Market Dynamics5.1 Key Market Drivers5.1.1 Patient shift towards regenerative medicines5.1.2 Increasing number of patients suffering with cancer5.2 Key Restraints5.2.1 Risk of contamination associated with the cell expansion process5.3 Key Market Opportunities5.3.1 Growing R&D Expenditure for Cancer Research5.4 Future Trend5.4.1 Extensive development in drug discovery5.5 Impact Analysis

6. Cell Expansion Market - North America Analysis6.1 North America Cell Expansion Market Revenue Forecasts and Analysis6.2 Positioning Of Key Players

7. North America Cell Expansion Market Analysis And Forecasts To 2027 - Product7.1 Overview7.2 North America Cell Expansion Market, By Product 2018 & 2027 (%)7.2.1 North America Cell Expansion Market Revenue and Forecasts to 2027, By Product (US$ Mn)7.2.1.1 North America Consumables Market Revenue and Forecasts to 2027, By Type (US$ Mn)7.2.1.1.1 North America Disposables Market Revenue and Forecasts to 2027, By Type (US$ Mn)7.2.1.2 North America Instruments Market Revenue and Forecasts to 2027, By Type (US$ Mn)7.3 Consumables7.3.1 Overview7.3.2 North America Consumables Market Revenue and Forecast to 2027 (US$ Mn)7.3.3 Reagents, Media & Serum7.3.3.1 Overview7.3.3.2 North America Reagents, Media & Serum Market Revenue and Forecast to 2027 (US$ Mn)7.3.4 Disposables7.3.4.1 Overview7.3.4.2 North America Disposables Market Revenue and Forecast to 2027 (US$ Mn)7.3.4.3 Culture Tissue Flasks7.3.4.3.1 Overview7.3.4.3.2 North America Culture Tissue Flasks Market Revenue and Forecast to 2027 (US$ Mn)7.3.4.4 Bioreactor Accessories7.3.4.4.1 Overview7.3.4.4.2 North America Bioreactor Accessories Market Revenue and Forecast to 2027 (US$ Mn)7.3.4.5 Other Disposables7.3.4.5.1 Overview7.3.4.5.2 North America Other Disposables Market Revenue and Forecast to 2027 (US$ Mn)7.4 Instruments7.4.1 Overview7.4.2 North America Instruments Market Revenue and Forecasts to 2027 (US$ Mn)7.4.3 Cell Expansion Supporting Equipment7.4.3.1 Overview7.4.3.2 North America Cell Expansion Supporting Equipment Market Revenue and Forecast to 2027 (US$ Mn)7.4.4 Bioreactors7.4.4.1 Overview7.4.4.2 North America Bioreactors Market Revenue and Forecast to 2027 (US$ Mn)7.4.5 Automated Cell Expansion Systems7.4.5.1 North America Automated Cell Expansion Systems Market Revenue and Forecast to 2027 (US$ Mn)

8. North America Cell Expansion Market Analysis And Forecasts To 2027 - Cell Type8.1 Overview8.2 North America Cell Expansion Market, By Cell Type 2018 & 2027 (%)8.2.1 North America Cell Expansion Market Revenue and Forecasts to 2027, By Cell Type (US$ Mn)8.3 Human Cells8.3.1 Overview8.3.2 North America Human Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.3 Adult Stem Cells8.3.3.1 Overview8.3.3.2 North America Adult Stem Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.4 Induced Pluripotent Stem Cells8.3.4.1 Overview8.3.4.2 North America Induced Pluripotent Stem Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.5 Embryonic Stem Cells8.3.5.1 Overview8.3.5.2 North America Embryonic Stem Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.6 Differentiated Cells8.3.6.1 Overview8.3.6.2 North America Differentiated Cells Market Revenue and Forecast to 2027 (US$ Mn)8.4 Animal Cells8.4.1 Overview8.4.2 North America Animal Cells Market Revenue and Forecast to 2027 (US$ Mn)

9. North America Cell Expansion Market Analysis- By Application9.1 Overview9.2 North America Cell Expansion Market, By Application 2018 & 2027 (%)9.3 Regenerative Medicine and Stem Cell Research9.4 Cancer and Cell-based Research9.5 Other Applications

10. North America Cell Expansion Market Analysis- By End User10.1 Overview10.2 North America Cell Expansion Market, By End User 2018 & 2027 (%)10.3 Biopharmaceutical And Biotechnology Companies10.4 Research Institutes10.5 Cell Banks10.6 Other End Users

11. Cell Expansion Market Revenue And Forecasts To 2027 - Geographical Analysis11.1 North America Cell Expansion Market, Revenue and Forecast to 202711.1.1 North America Cell Expansion Market, Revenue and Forecast to 2027 (US$ Mn)11.1.2 North America Cell Expansion Market, Revenue and Forecast to 2027, By Product (US$ Mn)11.1.2.1 North America Consumables Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.2.1.1 North America Disposables Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.2.2 North America Instruments Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.3 North America Cell Expansion Market, Revenue and Forecast to 2027, By Cell Type (US$ Mn)11.1.3.1 North America Human Cell Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.4 North America Cell Expansion Market, Revenue and Forecast to 2027, By Application (US$ Mn)11.1.5 North America Cell Expansion Market, Revenue and Forecast to 2027, By End User (US$ Mn)11.1.6 North America Cell Expansion Market, Revenue and Forecast to 2027, By Country (%)11.1.7 US11.1.8 Canada11.1.9 Mexico

12. North America Cell Expansion Market- Industry Landscape12.1 Overview12.2 Growth Strategies In The Cell Expansion Market, 2017-201912.3 Organic Growth Strategies12.3.1 Overview12.3.1.1 Recent Organic Developments By Players In The Cell Expansion Market12.4 Inorganic Growth Strategies12.4.1 Overview12.4.2 Recent Developments By Players In The Cell Expansion Market

13. Global Cell Expansion Market-Key Company Profiles13.1 BD13.1.1 Key Facts13.1.2 Business Description13.1.3 Financial Overview13.1.4 Product Portfolio13.1.5 SWOT Analysis13.1.6 Key Developments13.2 Merck KGaA13.3 Thermo Fisher Scientific, Inc.13.4 Terumo Corporation13.5 General Electric Company13.6 Corning Incorporated13.7 Miltenyi Biotec13.8 Danaher13.9 Lonza13.10 STEMCELL Technologies, Inc.

14. Appendix14.1 About the Publisher14.2 Glossary of Terms

For more information about this report visit https://www.researchandmarkets.com/r/gq37sj

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

The rest is here:
Insights on the Cell Expansion Industry in North America to 2027 - by Product, Cell Type, Application, End-user and Country - GlobeNewswire

NEW YORK, April 22, 2020 /PRNewswire/ --

KEY FINDINGSThe global artificial intelligence in healthcare market is set to register growth, projecting a CAGR of 38.05% during the forecast period, 2020-2028. The prominent drivers of market growth are estimated to be the rising big data in the healthcare industry, the growing use of AI in genetics, the emergence of personalized medicine in tests for clinical decision making, along with the creation of a real-time monitoring system due to AI.

Read the full report: https://www.reportlinker.com/p05242360/?utm_source=PRN

MARKET INSIGHTSThe utilization of AI in healthcare entails the use of software and algorithms for estimating the human perception for analyzing complex medical data, along with the relationship between treatments or prevention techniques and patient outcomes.The growing demand for real-time monitoring system is one of the key aspects propelling the growth of the global artificial intelligence in healthcare market.

The real-time monitoring devices like health monitoring devices or indicators track real-time health data of patients, which is increasing the demand for AI in healthcare.The devices also drive the relevancy of data interpretation and aid in reducing the time the patients spend in piecing data output.

In healthcare, the devices help in detecting and preventing undesirable patient outputs. The growing number of mobile devices integrated with artificial intelligence assists in the prediction of future outcomes with regard to health, which further benefits market growth.Medical practitioners are reluctant to adopt AI-based technologies, and this is restraining the growth of the market.The reluctance is because of the lack of data that identifies healthcare decisions.

Also, from a diagnostics point of view, AI systems fare less in terms of efficiency in comparison to conventional methods.The companies in the market are competing against each other by providing the same characteristics and similar prices.

The competitive rivalry is projected to be high during the forecast period.

REGIONAL INSIGHTSThe geographical segmentation of the global artificial intelligence in healthcare market includes the analysis of Europe, North America, Asia Pacific, and the rest of the world.Inkwood Research estimates the Asia Pacific region to be the fastest-growing region by the end of the forecast period.

The invention of new technologies, the presence of countries like China, Japan, Australia, and India, and the thriving artificial intelligence market, are the factors propelling the growth of the market.

COMPETITIVE INSIGHTSSome of the prominent companies operating in the market are Enlitic Inc, Next IT Corporation, Recursion, Welltok, GE Healthcare, Microsoft Corporation, etc.

Our report offerings include: Explore key findings of the overall market Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges) Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions Market Segmentation cater to a thorough assessment of key segments with their market estimations Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc. Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc. Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Companies mentioned1. DEEP GENOMICS INC2. ENLITIC INC3. GE HEALTHCARE4. GENERAL VISION INC5. GOOGLE6. IBM CORPORATION7. ICARBONX8. INTEL CORPORATION9. MICROSOFT CORPORATION10. NEXT IT CORPORATION11. NVIDIA CORPORATION12. ONCORA MEDICAL13. RECURSION PHARMACEUTICALS INC14. STRYKER CORPORATION15. WELLTOK INC

Read the full report: https://www.reportlinker.com/p05242360/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-artificial-intelligence-in-healthcare-market-is-set-to-register-growth-projecting-a-cagr-of-38-05-during-the-forecast-period-2020-2028--301045674.html

SOURCE Reportlinker

More:
The global artificial intelligence in healthcare market is set to register growth, projecting a CAGR of 38.05% during the forecast period, 2020-2028 -...

Its pretty hard to ignore the impact of Covid-19 on the global and domestic economy. But the shutdown in the U.S. economy, while swift, was also swiftly managed by the administration and Congress, as well as the Federal Reserve.This has helped buoy the markets after a precipitous initial drop. And it has allowed enough time for investors to process everything that has happened and reset their expectations looking away from certain risks and into cleaning-supply companies and biotech stocks.

Previous to Covid-19, there was the feeling the economy was nearing recession sometime this year. Now were in one.

However, this remains an uneven market. Big stocks like Amazon (NASDAQ:AMZN) and Netflix (NASDAQ:NFLX) are doing even better under these difficult conditions. But other consumer stocks arent.

Thats why I wanted to talk about an opportunity that doesnt have to do with consumer-driven stocks the seven beautiful biotech stocks to buy here. These companies are set up to endure long drug approval processes that happen over good times and bad.

Theyre built to be immune from general market forces, especially the big one these days consumer spending and to benefit from powerful technology thats popping up in all kinds of industries.

Source: Catalin Rusnac/ShutterStock.com

CRISPR is a Swiss biotech that is one of the leaders in CRISPR technology. This is a new and fast-growing field. CRISPR (it stands for clustered regularly interspaced short palindromic repeats) is a DNA segment containing short repetitions of base sequences.

By using these, scientists are learning to identify where there is a break in the pattern that may signal a disease and then repair (or edit) that sequence. This is a revolutionary concept in treating disease, since it is the first step toward personalized medicine.

Currently the research is hoping to build treatments to help battle many different cancers and other diseases. But eventually the technology can be applied to a much broader field of needs.

The company is well funded and will continue to make a difference, even sequencing Covid-19.

The stock is up 37% in the past year and over 30% in the past month.

Source: Pavel Kapysh / Shutterstock.com

Acceleron is a biopharmaceutical company that has been around since 2003. Last year was a wild ride for the firm, and the volatility continued into 2020.

In September, one of its drugs in trials was rejected by the FDA and the stock tanked. Then, shortly after that, its drug luspatercept, which treats a rare blood disorder, was approved.

And then, in late January, data from a Phase 2 trial of another drug it has in the approval process for pulmonary arterial hypertension (PAH), showed significant positive results in treating the disorder. This is the kind of situation that can attract big buying pressure on Wall Street of the kind I want to see inGrowth Investor.

Needless to say, the stock is now up 134% in the past year, and 38% in the past month.

One of its largest shareholders is Bristol Myers Squibb (NYSE:BMY). Acceleron had been doing a lot of work with Celgene when BMY bought Celgene. This is a great partnership to have when looking to market, manufacture and distribute these new drugs.

Source: Shutterstock

Neurocrine Bioscienceshas been in business for over 25 years and specializes in developing treatments for people suffering with neurological, endocrine and psychological disorders.

It currently has treatments for tardive dyskinesia and endometriosis. It has candidates for Parkinsons, uterine fibroids and congenital adrenal hyperplasia. Last year, there was talk that Biogen (NASDAQ:BIIB) may have been looking at NBIX as an acquisition to build on its own work in some of these sectors.

Its a solid company that has a good balance of revenue-generating drugs and a solid, focused drug pipeline. Neurocrine has a unique niche and will remain an attractive takeover target for larger pharmaceutical companies and biotechs.

The stock is up 17% for the past year, and 20% in the past month.

Source: Jarretera / Shutterstock.com

Galapagos is a Belgian company that specializes in small molecule and antibody therapies.

It was a solid performer and has been around for over 20 years. But its big break happened last year when Gileadapproached the company and offered it a $5 billion partnership deal. This brought the stock to the attention of many U.S. investors who hadnt paid much attention to it.

And by December, that partnership paid off. GILD filed with FDA for speedy review of filgotinib, a potential blockbuster drug that GLPG developed and had in Europe in Japan but not the U.S. The U.S. is the market where the money is made, since pricing is far more dynamic than in other countries.

The approval came in December. And this could mean big things for both companies. But since then, Covid-19 has taken the spotlight and Gileads remdesivir has been all the buzz.

GLPG stock is up over 80% in the past 12 months, and almost 45% in the past month. Its management has also been wise enough to partner with a genomics company that provides whats sometimes nicknamed the mother of all technologiesto help discover new treatments and drug combinations.

Source: Eyesonmilan / Shutterstock.com

Incyte has been around since the early 1990s and is good-sized biopharmaceutical company with a $21 billion market capitalization.

Currently it has two drugs in the marketplace, one of those is in the US. Its big drug is Jakafi (ruxolitinib), which treats a rare form of blood cancer and is also approved to manage acute graft-versus-host disease in adults.

It also has a drug that it acquired from ARIAD Pharmaceuticals for European distribution. Its Iclusig (ponatinib) is used to treat leukemia, and INCY stock hopes to make the drug available in the U.S. after approval from the FDA.

Incyte also has a good number of drugs in the pipeline and has the financial wherewithal to keep moving them forward, even now.

The stock is up 36% in the past 12 months, and over 60% in the past month.

Source: madamF / Shutterstock.com

Regeneron is one of those biotech stocks that has been a direct Covid-19 beneficiary.

It has a number of drugs in the market and around 30 drugs in its pipeline. It has been around since 1988 and has a $62 billion market cap, so this is no one-trick pony rolling the dice on a potential blockbuster. It has built its reputation over time, delivering solid drugs in important sectors.

But the added juice at this point is its arthritis drug Kevzara that it co-markets with Sanofi (NASDAQ:SNY). It has been given to patients in China and New York (the co-founder of Regeneron is from Queens) but the testing isnt broad enough to deliver any conclusive information.

Obviously, the bet on Kevzara being a treatment is just that, a bet. But it has brought more attention to REGN, which is a quality pharma. And Regeneron also has its eye on the big picture of next-generation technology to supercharge its genomics research at the Regeneron Genetics Center.

The stock is up almost 62% in the past year and up 22% in the past month.

Source: Michael Moloney / Shutterstock.com

Gilead has been a big name among biotech stocks for a long time. It was a key player in finding a treatment for HIV/AIDS. And was also a pioneer in finding a highly effective once-a-day regimen for hepatitis C.

While it still makes a good amount of money from these blockbusters, it hadnt had a big hit in a while and the stock flat-lined as investors wondered if its best days were behind it.

But it has made some interesting acquisitions and partnerships in the past couple years, one of those being with Galapagos.

And now, remdesivir is in two Phase 3 clinical trials as a treatment for Covid-19. This, along with the promising partnership with GLPG stock thats already delivering results, promises that GILD could beback in the running with two potential blockbusters. Even one would be great news.

The stock is on the move, up 30% in the past 12 months, and 13% in the past month. And it is still off its 2015 highs, so theres plenty of headroom if either or both these drug live up to their promise.

Gilead is one of the big kahunas in this space, and now a household name, thanks to the fight against Covid-19. It, too, is partnering with smaller labs to harness the power of the game-changing technology of our time: artificial intelligence (AI).

If artificial intelligence sounds futuristic, even far-fetched well, keep in mind, youre already using it every day. If youve ever usedAlphabets(NASDAQ:GOOG, NASDAQ:GOOGL) Google Assistant orApples(NASDAQ:AAPL) Siri if youve hadNetflix(NASDAQ:NFLX) recommend a movie orZillow(NASDAQ:Z) recommend a house even an email spam filter then youve used artificial intelligence.

In this new world of AI everywhere, data becomes a hot commodity.

As scientists find even more applications for artificial intelligence from hospitals to retail to self-driving cars its incredible to imagine how much data will be involved.

To create AI programs in the first place, tech companies must collect vast amounts of data on human decisions. Data is what powers every AI system. As one AI researcher from the University of South Florida puts it, data is the new oil.

To cash in, youll want the company that makes the brain that all AI software needs to function, spot patterns and interpret data.

Its known as the Volta Chip and itswhat makes the AI revolution possible.

You dont need to be an AI expert to take part.Ill tell you everything you need to know, as well as my buy recommendation, inmy special report forGrowth Investor,The A.I. Master Key. The stock is still under my buy limit price so youll want to sign up now. That way, you can get in while you can still do so cheaply.

Click here for a free briefing on this groundbreaking innovation.

Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system withreturns rivaling even Warren Buffett. In his latest feat, Louis discovered the Master Key to profiting fromthe biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters.

Read the rest here:
7 Beautiful Biotech Stocks to Buy Here - Investorplace.com

Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don't put up a paywall we believe in free public access to information. Although underresourced & primarily volunteer-based, we endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources. Our goal and mission is to provide free and alternative access to impartial information, fighting media monopolization and adhering to honesty, neutrality, fairness, transparency and independence in collection and dissemination of information. It is a bumpy road with all sorties of difficulties. (Media ownership in Australia is one of the most concentrated in the world (more on this!). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn moreWe can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate.If you like what we do & would like to buy us a coffee (or lots of coffees), please know it's greatly appreciated. All donations are kept completely private and confidential.Thank you very much in advance!

Read more:
Weizmann Institute of Science Began to Conduct Coronavirus Testing Today - Mirage News

Dublin, April 09, 2020 (GLOBE NEWSWIRE) -- The "Global Precision Medicine Market 2019-2025" report has been added to ResearchAndMarkets.com's offering.

The global precision medicine market is estimated to grow at a CAGR of 9.8% during the forecast period. Factors such as the increasing prevalence of cancer, central nervous system disorder, and respiratory diseases coupled with the increasing focus on researches focusing on the development of precision medicine are augmenting the market growth. Moreover, the growing focus on the biomarkers is promising ample opportunities for the growth of the personalized medicine market across the globe.

The report analyzes the global precision medicine market on the basis of technology, application, end-use, and geography. On the basis of technology, the market is genomics, transcriptomics, and epigenomics. Based on the application, the market is classified into oncology, neurology, immunology, and others. Based on the end-user, the market is classified into pharmaceutical companies, diagnostic companies, and healthcare IT companies.

The advancement in genomic and clinical science have established advanced prospects to further customize healthcare to every patient. The Center for Individualized Medicine at Mayo Clinic is practicing personalized medicine and using it to the complete spectrum of healthcare with the use of sophisticated techniques of molecular analysis and genomic sequencing. Microbiome Program by Mayo Clinic enables to understand the cause of transmitting the infection through bacteria. It investigates several questions under the program, such as if microbial communities in the colon could be responsible for irritable bowel symptoms and gluten sensitivity. In addition, it examines the colon organisms affect other body parts, including the joints. The program explores the genetic code of the microorganism of the body. It uses advanced techniques for profiling the microbiome of an individual to detect, prevent and diagnose infections and other diseases. These rising focus of medical centers towards microbiome program for personalized medicine is expanding the scope for the growth of the global personalized medicine market.

Geographically, the market is analyzed into North America, Europe, Asia-Pacific, and the Rest of the World. North America is estimated to contribute a significant market share in the global precision medicine industry over the forecast period. Increasing prevalence of cancer, respiratory diseases, and neurological disorders are augmenting the growth of the North America precision medicine market. Moreover, the presence of prominent institutes and market players focusing on the development of precision medicine through researches are also driving the market growth of the region.

Furthermore, the market is characterized by the presence of several players including F. Hoffmann La Roche Ltd., Abbott Laboratories Inc., Pfizer Inc., Qiagen NV, Teva Pharmaceutical Industries Ltd., Eagle Genomics, and many others. These players adopt various strategies to capitalize on market growth opportunities. For instance, in October 2018, Eagle Genomics partnered with Microsoft Genomics to tackle the computational challenges of the genomics era. The aim of the partnership was to introduce the scale and power of the cloud to precision medicine, across the production of fundamental research and core services.

The Report Covers:

Key Topics Covered:

1. Report Summary1.1. Research Methods and Tools1.2. Market Breakdown1.2.1. By Segments1.2.2. By Geography

2. Market Overview and Insights2.1. Scope of the Report 2.2. Analyst Insight & Current Market Trends2.2.1. Key Findings2.2.2. Recommendations2.2.3. Conclusion2.3. Rules & Regulations

3. Competitive Landscape3.1. Company Share Analysis3.2. Key Strategy Analysis3.3. Key Company Analysis3.3.1. F. Hoffmann La Roche Ltd.3.3.1.1. Overview3.3.1.2. Financial Analysis3.3.1.3. SWOT Analysis3.3.1.4. Recent Developments3.3.2. Abbott Laboratories Inc.3.3.2.1. Overview3.3.2.2. Financial Analysis3.3.2.3. SWOT Analysis3.3.2.4. Recent Developments3.3.3. Pfizer Inc.3.3.3.1. Overview3.3.3.2. Financial Analysis3.3.3.3. SWOT Analysis3.3.3.4. Recent Developments3.3.4. Qiagen NV3.3.4.1. Overview3.3.4.2. Financial Analysis3.3.4.3. SWOT Analysis3.3.4.4. Recent Developments3.3.5. Teva Pharmaceutical Industries Ltd. 3.3.5.1. Overview3.3.5.2. Financial Analysis3.3.5.3. SWOT Analysis3.3.5.4. Recent Developments

4. Market Determinants4.1. Motivators4.2. Restraints4.3. Opportunities

5. Market Segmentation5.1. Global Precision Medicine Market by Technology 5.1.1. Genomics5.1.2. Transcriptomics5.1.3. Epigenomics5.2. Global Precision Medicine Market by Application5.2.1. Oncology5.2.2. Neurology 5.2.3. Immunology5.2.4. Others (Respiratory)5.3. Global Precision Medicine Market by End-Use5.3.1. Pharmaceutical Companies5.3.2. Diagnostic Companies5.3.3. Healthcare IT Companies

6. Regional Analysis6.1. North America6.1.1. United States6.1.2. Canada6.2. Europe6.2.1. UK6.2.2. Germany6.2.3. Italy6.2.4. Spain6.2.5. France6.2.6. Rest of Europe6.3. Asia-Pacific6.3.1. China6.3.2. Japan6.3.3. India6.3.4. Rest of Asia-Pacific6.4. Rest of the World

7. Company Profiles

Companies Mentioned

Story continues

For more information about this report visit https://www.researchandmarkets.com/r/kdkbgk

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Originally posted here:
Outlook on the Worldwide Precision Medicine Industry to 2025 - Growing Focus on Biomarkers is Promising Ample Opportunities - Yahoo Finance

SALT LAKE CITY, April 08, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, announced today that due to the impact of the global COVID-19 pandemic, the company is withdrawing its fiscal year 2020 financial guidance.

Prior to mid-March we were experiencing volume trends consistent with our expectations across all products; however, recent social distancing guidelines have had a significant impact on test volume trends in late March and into the fiscal fourth-quarter, said R. Bryan Riggsbee, interim president and CEO and chief financial officer at Myriad Genetics. Our priority as an organization during the coronavirus pandemic has been to maintain business continuity and access to testing, while ensuring the safety of our employees and customers. As an organization we have taken steps to advance these dual aims, and I am very proud of how the Myriad team has responded to the crisis.

In responding to the pandemic, Myriad has made several changes to its business practices to promote the safety of both customers and employees including ceasing in-office sales calls and implementing virtual selling, granting all non-essential personnel the ability to work from home, enabling direct sample collection for patients and implementing policies to improve laboratory personnel safety.

While the uncertain timeframe of the Coronavirus pandemic makes it difficult to predict future business trends for the company, the company will provide an update on its business, including the impact of COVID-19, on its next quarterly earnings call.

About Myriad GeneticsMyriad Genetics, Inc. is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prequel, ForeSight, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to maintaining the Companys global leadership in precision medicine and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of the Companys existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to the Companys ability to successfully transition from its existing product portfolio to our new tests; risks related to changes in the governmental or private insurers reimbursement levels for the Companys tests or the Companys ability to obtain reimbursement for its new tests at comparable levels to its existing tests; risks related to increased competition and the development of new competing tests and services; the risk that the Company may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that the Company may not successfully develop new markets for its molecular diagnostic tests and pharmaceutical and clinical services, including the Companys ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying the Companys molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating the Companys laboratory testing facilities; risks related to public concern over the Companys genetic testing in general or the Companys tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to the Companys ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to the Companys ability to successfully integrate and derive benefits from any technologies or businesses that it licenses or acquires; risks related to the Companys projections about the potential market opportunity for the Companys products; the risk that the Company or its licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying the Companys tests; the risk of patent-infringement claims or challenges to the validity of the Companys patents; risks related to changes in intellectual property laws covering the Companys molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that the Company may be unable to comply with financial operating covenants under the Companys credit or lending agreements; the risk that the Company will be unable to pay, when due, amounts due under the Companys credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of the Companys most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in the Companys Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Story continues

See the article here:
Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic - Yahoo Finance

April 8, 2020 The scientific community is learning more about the impact and interaction of cardiovascular diseases with novel coronavirus (COVID-19, SARS-CoV-2), including the impact of drug therapies being used and their negative cardiovascular impact. Together, the American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Rhythm Society (HRS) April 8 jointly published a new guidance, Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 19) Treatment, to detail critical cardiovascular considerations in the use of hydroxychloroquine and azithromycin for the treatment of COVID-19.[1]

This guidance is published in Circulation, the journal of the American Heart Association, the Journal of the American College of Cardiology (JACC), and Heart Rhythm Journal, the official journal of the HRS.

The antimalarial medication hydroxychloroquine and the antibiotic azithromycin are currently gaining attention as potential treatments for COVID-19, and each have potential serious implications for people with existing cardiovascular disease. Complications include severe electrical irregularities in the heart such as arrythmia (irregular heartbeat), polymorphic ventricular tachycardia (including Torsade de Pointes) and long QT syndrome, and increased risk of sudden death. The effect on QT or arrhythmia of these two medications combined has not been studied.

The AHA, the ACC and the HRS guidance for health care professionals includes additional mechanisms to reduce the risk of arrhythmias. Steps outlined: Electrocardiographic/QT interval monitoring; Withhold hydroxychloroquine and azithromycin in patients with baseline QT prolongation (e.g. QTc 500 msec) or with known congenital long QT syndrome; Monitor cardiac rhythm and QT interval; withdrawal of hydroxychloroquine and azithromycin if QTc exceeds a present threshold of 500 msec; In patients critically ill with COVID-19 infection, frequent caregiver contact may need to be minimized, so optimal electrocardiographic interval and rhythm monitoring may not be possible; Correction of hypokalemia >4mEq/L and hypomagnesemia >2mg/dL; and Avoid other QTc prolonging agents whenever feasible.

The statement also includes a table rating potential adverse cardiac events of medications currently being repurposed for COVID-19 treatment, such as chloroquine and lopinavir/ritonavir (antimalarial and antiviral agents, respectively).

The urgency of COVID-19 must not diminish the scientific rigor with which we approach COVID-19 treatment. While these medications may work against COVID-19 individually or in combination, we recommend caution with these medications for patients with existing cardiovascular disease, said Robert A. Harrington, M.D., FAHA, president of the American Heart Association, Arthur L. Bloomfield Professor of Medicine and chair of the department of medicine at Stanford University.

We are united in our mission to achieve optimal, quality care for our patients, and we must continue to be vigilant in assessing the potential complications of all medications during this crisis, stated Athena Poppas, M.D., president of the American College of Cardiology, professor of medicine at Brown University and chief of cardiology and director of the Lifespan Cardiovascular Institute at Rhode Island, the Miriam and Newport hospitals in Providence, Rhode Island.

Given the potential for increased risks related to combinations of medications that prolong the QT interval, we urge careful consideration to ensure patients with cardiovascular disease or others at increased risk can be monitored appropriately, stated Andrea M. Russo, M.D., president of the Heart Rhythm Society, director of Electrophysiology and Arrhythmia Services at Cooper University Hospital, director of the CCEP Fellowship Program, and professor of medicine at Cooper Medical School of Rowan University in Camden, New Jersey.

The statement is also co-authored by Dan M. Roden, M.D., C.M., interim division chief of cardiovascular medicine, senior vice president for personalized medicine, faculty of the clinical cardiac electrophysiology program, Sam Clark Chair in Experimental Therapeutics, professor of pharmacology and professor of biomedical informatics at Vanderbilt University in Nashville, Tennessee.

AHA COVID-19 newsroom

For more information: HRSonline.org, acc.org

COVID-19 Hydroxychloroquine Treatment Brings Prolonged QT Arrhythmia Issues

No Evidence Supporting Discontinuing RAAS Inhibitors in COVID-19 Patients in NEJM Article

ESC Council on Hypertension Says ACE-I and ARBs Do Not Increase COVID-19 Mortality

FDA Approves ECMO to Treat COVID-19 Patients

Cardiology Related COVID-19 News and Videos

VIDEO: What Cardiologists Need to Know about COVID-19 Interview with Thomas Maddox, M.D.

Reference:

1. Dan M. Roden , Robert A. Harrington, Athena Poppas, and Andrea M. Russo. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Circulation. Originally published 8 Apr 2020. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047521.

See the original post here:
AHA, ACC, HRS Caution Use of COVID-19 Therapies Hydroxychloroquine and Azithromycin in Cardiac Patients - Diagnostic and Interventional Cardiology

New Jersey, United States:The Personalized Medicine Market is analyzed in depth in the report, with the primary aim of providing accurate market data and useful recommendations so that players can achieve strong growth in the future. The report is compiled by experts and experienced market analysts, which makes it very authentic and reliable. Readers have a thorough analysis of historical and future market scenarios to get a good understanding of market competition and other important issues. The report provides comprehensive information on market dynamics, key segments, key players and various regional markets. It is a complete set of in-depth analysis and research on the Personalized Medicine market.

The authors of the report highlighted lucrative business prospects, eye-catching trends, regulatory situations and Personalized Medicine market price scenarios. It is important to note that the report includes a detailed analysis of the macroeconomic and microeconomic factors affecting the growth of the Personalized Medicine market. It is divided into several sections and chapters so that you can easily understand every aspect of the Personalized Medicine market. Market participants can use the report to take a look at the future of the Personalized Medicine market and make significant changes to their operating style and marketing tactics in order to achieve sustainable growth.

Global Personalized Medicine Market was valued at USD 96.97 Billion in 2018 and is expected to witness a growth of 10.67% from 2019-2026 and reach USD 217.90 Billion by 2026.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=SIM&utm_medium=001

Key Players Mentioned in the Personalized Medicine Market Research Report:

The competitive landscape of the Personalized Medicine market is examined in detail in the report, with a focus on the latest developments, the future plans of the main players and the most important growth strategies that they have adopted. The analysts who have written the report have drawn a picture of almost all the main players in the Personalized Medicine market and highlighted their crucial commercial aspects such as production, areas of activity and product portfolio. All companies analyzed in the report are examined on the basis of important factors such as market share, market growth, company size, production volume, turnover and profit.

Personalized Medicine Market: Segmentation

The report provides an excellent overview of the key Personalized Medicine market segments, focusing on their CAGR, market size, market share and potential for future growth. The Personalized Medicine market is mainly divided by product type, application and region. Each segment in these categories is the subject of in-depth research to familiarize yourself with its growth prospects and key trends. The segment analysis is very important to identify the most important growth pockets of a global market. The report provides specific information on market growth and demand for various products and applications so that players can focus on profitable sectors of the Personalized Medicine market.

Ask For Discount (Special Offer: Get 25% discount on this report) @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=SIM&utm_medium=001

Table of Content

1 Introduction of Personalized Medicine Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Personalized Medicine Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model5.1 Overview

6 Personalized Medicine Market, By Solution6.1 Overview

7 Personalized Medicine Market, By Vertical7.1 Overview

8 Personalized Medicine Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Complete Report is Available @https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=SIM&utm_medium=001

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

https://www.marktforschungsblogs.com/

Tags: Personalized Medicine Market Size, Personalized Medicine Market Trends, Personalized Medicine Market Forecast, Personalized Medicine Market Growth, Personalized Medicine Market Analysis

Continued here:
Personalized Medicine Market Increasing Demand with Leading Player, Comprehensive Analysis and Forecast 2026 - Science In Me

SALT LAKE CITY, April 08, 2020 (GLOBE NEWSWIRE) -- Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group (OTC PINK: PRED) (Predictive or The Company), today shared that its distribution partner, Wellgistics, has submitted an initial order for immediate delivery of one (1) million units of the Assurance AB COVID-19 IgM/IgG Rapid Antibody Test (Assurance AB) intended for use by laboratories and healthcare workers at the point-of-care in the U.S.

We have been working diligently withWellgisticsto get this first order put in motion, even prior to making our partnership announcement on April 3, said Bradley Robinson, CEO of Predictive Technology Group. This country is in high need of theAssurance ABtesting for point of care use and we have brought all resources to bear to bring this product to the United States. Wellgistics has provided us with state-by-state demand guidance, to ensure that regions with the most urgent need have first access to the test. Our main priorities will be to focus on servicing those areas, Robinson continued.

When our partnership with Predictive was announced last week, our team was very aware of the coming tsunami wave of interest for this test, said Brian Norton, CEO of Wellgistics. This demand grows each day as more attention hits the media and is recognized as a viable solution toward identifying immunity and allowing people to go back to work. Presently, the Wellgistics team is hyper focused on closing the final gaps of the complex web of international logistics. We feel great about where we are, and we will provide new updates as quickly as they are available.

Predictive announced website updates relating to Assurance AB including:Instructions For Use, Quick Reference Guide and Fact Sheet for laboratories and healthcare workers at the point-of-care. The website also includes an instructional video on administering the Assurance AB test.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize and personalize precision patient care. The Companys entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests and companion therapeutics in order to support a patient from diagnosis through treatment.

Dedicated to identifying the barriers that impact lifelong health through our genetic library, genomic mapping and individualized diagnostics, Predictives tests and products empower clinicians to provide their patients with the highest level of care. For more information, visit http://www.predtechgroup.com

About Predictive Laboratories, Inc.

Predictive Laboratories molecular and genetic diagnostics focus on hard-to-diagnose and hard-to-detect diseases. Leveraging its vast genetic library, Predictive offers earlier detection of a variety of diseases through genetic assessments to guide personalized precision medicine.

Equipped with a state-of-the-art CAP and CLIA accredited laboratory, Predictive operations perform next-generation sequencing experiments, including whole exome sequencing, gene and genetic marker panels, and low-pass whole genome analysis of embryos for aneuploidies. Predictive arms physicians with the most robust diagnostic tools to provide personalized precision treatment for their patients. For more information, visit http://www.predictivelabs.com

Forward-Looking Statements:

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Story continues

Contacts:

Predictive LaboratoriesInfo@predictivelabs.com855-497-3636

Investor ContactJeremy FefferLifeSci Advisorsjeremy@lifesciadvisors.com212-915-2568

Read more here:
Predictive Technology Group Announces Initial Order of One Million Units of the Assurance AB COVID-19 IgM/IgG Rapid Antibody Test from Distribution...

Global Nucleic Acid Isolation and Purification Market to Reach $3,835.2 Million by 2029

NEW YORK, April 9, 2020 /PRNewswire/ --

Read the full report: https://www.reportlinker.com/p05881508/?utm_source=PRN

Key Questions Answered in this Report: What are the major market drivers, challenges, and opportunities in the global nucleic acid isolation and purification market? What are the key development strategies which are being implemented by major players in order to sustain in the competitive market? How each segment of the market is expected to grow during the forecast period from 2020 to 2029 based on o product type: instrument and consumables (kits and reagents) o end User: academic research institutes, pharmaceutical and biotechnology companies, applied testing, contract research organizations, and clinical diagnostic centers o region, North America, EMEA, Asia-Pacific, and Latin America Which are the leading players with significant offerings to the global nucleic acid isolation and purification market? What is the expected market dominance for each of these leading players? Which companies are anticipated to be highly disruptive in the future and why? What are the challenges in the nucleic acid isolation and purification market?

Global Nucleic Acid Isolation and Purification Market Forecast, 2020-2029

The nucleic acid isolation and purification industry analysis projects the market to grow at a significant CAGR of 5.98% during the forecast period, 2020-2029. The nucleic acid isolation and purification market generated $2,273.9 million revenue in 2020, in terms of value. The nucleic acid isolation and purification market growth has been primarily attributed to the major drivers in this market, such as growing number of genetic tests, increasing demand for reliable next-generation sequencing (NGS) results, rise in the prevalence of infectious diseases, increasing research funding in the field of molecular biology, and increase in awareness and acceptance of personalized medicine on a global level. However, genomic data protection, high cost of automated instruments, and rigid regulatory standards are some of the factors expected to retrain the market growth.

Expert Quote

"As molecular diagnostic testing moves into the clinical laboratory environment, products used to collect and process samples will need to be standardized"

Scope of the Market Intelligence on Nucleic Acid Isolation and Purification Market

The nucleic acid isolation and purification research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers. In addition, the study also includes exhaustive information on the drivers, restraints opportunities, perception of the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global nucleic acid isolation and purification market.

Market Segmentation

The nucleic acid isolation and purification market (on the basis of product type) is segmented into instruments and consumables (kits and reagents).

The kits segment (on the basis of technology) has been classified into magnetic particle technology, silica technology, and other technologies. The other technologies have been broadly bifurcated into anion-exchange technology, lysis, precipitation-based chemistries, organic extraction, fluorescence, and other kits technologies.

Further, the instruments (on the basis of technology) has been classified into automated spin-column based and bead-based. The bead-based technology has been further bifurcated into magnetic bead-based and automated liquid handling.

The nucleic acid isolation and purification market (on the basis of applications) is segmented into PCR, qPCR, NGS, cloning, microarray, blotting techniques, and other applications.

The nucleic acid isolation and purification market (on the basis of end-user) is segmented into academic research institutes, pharmaceutical and biotechnology companies, applied testing, biobanks, contract research organizations, hospital research laboratories, and clinical diagnostic centers.

The nucleic acid isolation and purification market (on the basis of region) is segmented into North America, EMEA, Asia-Pacific, and Latin America.

Key Companies in the Nucleic Acid Isolation and Purification Market

The key manufacturers who have been contributing significantly to the nucleic acid isolation and purification market are Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F.Hoffmann-La Roche AG, Illumina, Inc., General Electric Company (GE), New England Biolabs, Inc., Promega Corporation, Merck KGaA, Takara Bio Inc., QIAGEN N.N., Thermo Fisher Scientific Inc., and Promega Corporation, among others.

Countries Covered North America U.S. Canada Europe, Middle East & Africa (EMEA) Latin America (LATAM) Asia-Pacific China Japan Rest-of-APAC

Read the full report: https://www.reportlinker.com/p05881508/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Story continues

View original content:http://www.prnewswire.com/news-releases/the-nucleic-acid-isolation-and-purification-industry-analysis-by-bis-research-projects-the-market-to-grow-at-a-significant-cagr-of-5-98-during-the-forecast-period-2020-2029--301038446.html

SOURCE Reportlinker

Read the original post:
The nucleic acid isolation and purification industry analysis by BIS Research projects the market to grow at a significant CAGR of 5.98% during the...

Theres nothing better as an investor than owning shares of companies that improve our lives. At the top of that list is companies that help us live healthier, longer lives.

Source: Shutterstock

Back in November which seems like an eternity ago I wrote that 2020 would be the Year of Biotech. Neither I nor anyone else knew how critical medical sciences and healthcare would become just a few months later amid a worldwide pandemic.

I still see 2020 as the Year of Biotech.

These stocks have shown relative strength in the bear market, and the current crisis gives us a glimpse of the innovative breakthroughs coming our way including efforts to fight the coronavirus.

In a volatile stock market like this, you can buy most stocks at a massive discount. Big names are down 20% 30% even 50%. Some small-cap stocks have slid even more.

This rare situation has opened up an unusual buying opportunity that we havent seen for at least the past decade or longer.

Fundamentally, the investment mega-trends Im following including in my new Crisis and Opportunity Portfolio are still on track. The coronavirus has scrambled everyones plans for the moment, but it wont last. The market has recovered from every past bear market, and were seeing glimmers of hope in the number of new cases around the world.

Ive been saying for more than week now that its time to start investing in stocks again. Believe me, trying to pick an exact bottom isnt worth the risk. Instead, you have to focus on the trends that will spawn the markets next big winners.

Biotechnology is one of these unstoppable mega-trends.

In 2019, before the coronavirus was on anyones mind, investors poured $13.9 billion into biotech startups. That was $4 billion less than 2018s record-breaking number but still higher than any other year on record.

The industry was climbing to new heights as companies began using next-generation technologies like artificial intelligence (AI) to find new drugs for diseases like cancer quicker and cheaper than ever before.

Another cutting-edge technology thats been on the rise is genomics, which will usher in a new era of personalized medicine for each patient as well as speed up the creation of new drugs.

And at this particular moment, it makes sense that investors would take notice as biotechs around the world are on high alert to find better drugs and/or a vaccine to tame the coronavirus.

Indeed, the sector has held steady through the recent volatility. Its one of the broader markets top performers.

So far this year, the S&P 500 is down more than 17% while theVanEck Vectors Biotech ETF (NASDAQ:BBH) is down closer to 5.6%. Thats far better than some of the other sectors that you might think would be strong right now like household products and food and staples retailing, which are both down 15%, according to Fidelity.

Yes, many biotech stocks are down at the moment. But that sets up an incredible chance to get some of the best at a discount.

Right now, more than 140 experimental coronavirus treatments and vaccines are in the works worldwide, according to theWall Street Journal. Researchers are moving at record pace, setting up 254 clinical trials to test drugs and/or vaccines in a matter of weeks or days.

Whether a given company is a part of this effort or not, nearly every biotech has been impacted by the pandemic. For instance, clinical trials are getting pushed back while healthcare facilities around the globe have shut down for fear of spreading the virus.

But the delay is short term. And longtimeMoneyWirereaders know that we focus on the long-term big picture.

Artificial intelligence and genomics already play a key role in the biotech industry as companies try to find a workable solution for whats ailing all of us.

And unlike the recent focus on producing protective equipment and coronavirus tests that will likely fizzle after the worst has passed,the use of these technologies will only continue to grow.

My #1 stock in theCrisis and Opportunity Portfoliothat I just released last week is a great example. The company uses AI in its predictive analytics to improve patient care and lower costs for insurance companies. Part of that involves the exploding trend of telehealth.

Telehealth includes the virtual doctors visits that are keeping us all out of waiting rooms during the pandemic. But I suspect doctors and patients alike will stick with the convenience and efficiency of the service long after the current crisis passes.

This stock lost a lot of ground in the sell-off, but it is already up 33% since I recommended it last Wednesday. The company is forecast to deliver 61% annual revenue growth and has a clear path to profitability, which is important when investing in smaller companies. I see a lot more upside to come.

Finding the best small companies in the best industries like biotech that will see the biggest gains as we recover is what my newCrisis and Opportunity Portfoliois all about.

Ive handpicked the companies best positioned to soar, and were adding them strategically one by one. Thats the smartest way to buy in this still-volatile market.

The current selling is setting up amazing buying opportunities in investment trends that wont slow due to the pandemic. The key is knowingwhich ones represent the best potential over the long term.

Matthew McCall left Wall Street to actually help investors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. The power of being first gave Matts readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now.Matt does not directly own the aforementioned securities.

Original post:
Biotech Stocks: Big Buying Opportunities in 2020s Sector of the Year - Investorplace.com

SOUTH PLAINFIELD, N.J., April 6, 2020 /PRNewswire/ -- Accurate Diagnostic Laboratories (ADL) and Rutgers University Cell & DNA Repository (RUCDR), through its Clinical Genomics Laboratory, are pleased to announce a joint mission aligning their efforts around improving testing capacity and service for the hospital inpatient population, health care providers and workers, first responders and patients.The relationship will facilitate providing high through-put and industry-leading turn around time for COVID-19 testing, also capitalizing on new methods to test. ADL and RUCDR have a long-standing relationship, where ADL performs diagnostic testing for RUCDR clinical trials, which aides in their data repository management. RUCDR, in conjunction with ADL's clinical client-base, fast-tracked the validation and verification of new testing methodologies, including saliva, for SARS-CoV-2 COVID-19. These alternate collection options will catapult the access of testing and screening to our most needed population."ADL's laboratory diagnostic capabilities, steeped in a tradition of offering the latest diagnostic technology offerings, is proud to expand our relationship with a local, world-renowned institution in Rutgers University Cell & DNA Repository laboratory.We want to do our mutual part to address the need for improved COVID-19 testing access, particularly for our front-line health care workers, hospital inpatient population, and first responders, by utilizing new collection and testing methods," says ADL's CEO, Rupen Patel.This is a game-changer for the market as "saliva testing will help with the global shortage of swabs for sampling and increase testing of patients, as it will not require health care professionals to collect samples," said Dr. Andrew Brooks, COO and director of technology development at RUCDR Infinite Biologics.He is also a professor in the Department of Genetics at Rutgers University-New Brunswick.As far as we know, we are the first and only laboratory to perform a significant validation and verification on multiple specimen types and not rely solely on the use of contrived samples.Accurate Diagnostic would like to formally thank those health care providers and health systems that assisted in the process to get this testing off the ground.

About Accurate Diagnostic Labs: Accurate Diagnostic Labs is one of the largest privately held, boutique, full-service clinical laboratories in the country.ADL, as a full-service core laboratory, proudly works with various entities on laboratory testing for clinical trial drug development and data repository in various market footprints to progress the field of disease state management and personalized medicine. With our local headquarters based in Central New Jersey, we pride ourselves in working with various healthcare corporations, institutions, health systems, and the local providers in the metropolitan area with the common goal of improving local and national healthcare.

Contact Information for ADL: For more information on ADL, please call at 732-839-3300 or visit online at http://www.accuratediagnosticlabs.com.

About RUCDR:RUCDR Infinite Biologics, which is part of Rutgers'Human Genetics Institute of New Jersey, is the world's largest university-based cell and DNA repository. Its mission is to understand the genetic causes of common, complex diseases and to discover diagnoses, treatments and cures for them. The organization collaborates with researchers in the public and private sectors throughout the world, providing the highest quality bio-banking services and biomaterials, as well as scientific and technical support.

Related Files

RUCDR ADL press release.docx

Related Images

rucdr.pngRUCDR

adl.pngADL

More:
Accurate Diagnostic Laboratories and Rutgers University Cell & DNA Repository Lab Work Together to Change the COVID-19 Testing Landscape - WFMZ...

Recently, as I was scheduling a routine procedure, the nurse asked for my fax number so she could send me the pre-op procedures. A fax machine in todays age? I was flabbergasted, as this was from an affiliate of one of the most sophisticated medical institutions in the United States, if not the world. I asked her to send me an email, and she indicated her systems were not equipped to do that but she might be able to scan the instructions and email them to me.

In light of the sweeping spread of Covid-19 and the increased pressure that has been and will continue to be brought to bear on the healthcare system, my experience becomes almost chilling.

As Cynthia Cox, director of the Peterson-Kaiser Health System Tracker recently commented to Vox: The coronavirus outbreak is already exposing inefficiencies and inequities in our health system, and it is likely to put much more strain on the system in the coming weeks.

And yet, we shouldnt need a pandemic to inform us that we need to bring our healthcare administration practices into modernity or to show investors the opportunity they have to bring about much-needed change.

My fax experience indicates that one major area to address is the antiquity of our healthcare system. In a time when our leaders and healthcare providers now face real concerns about Covid-19s potential to overwhelm our facilities and drain our resources, we have to wonder could the application of modern technology have improved our ability to handle a pandemic? The answer seems surely to be yes.

It is mind-boggling how healthcare practices stand in stark contrast to how advances in technology and science have dramatically improved diagnosing and treating a host of issues. In this context, profiting as an investor doesnt require one to be steeped in science or healthcare. In fact, one might argue that its best to come from the outside and apply a fresh perspective, as has been the case with many recent healthcare-focused entrepreneurs.

The marketplace for healthcare is massive; it literally applies to everyone. In the US alone, healthcare represents over $3 trillion or 18% of GDP. Its perplexing how an industry so large and all-consuming could be forced to rely on something as outdated as the fax machine.

The size, growth and dysfunction in healthcare lead me to believe there are few investment environments as fruitful as those concentrating on improving many key aspects of healthcare. There are enormous opportunities in biotechnology that are now possible due to massive leaps in computing power and cost, but I believe there are also equal opportunities to improve the actual processes associated with delivering healthcare. In the latter category, one is not required to have a deep science or medical aptitude to pursue or capitalize on.

It is these areas that I am most excited about, as they present the possibilities of applying otherwise-available technology to improving quality and reducing costs. According to Harry Glorikian in Moneyball Medicine, There are also substantial wastes and inefficiencies in healthcare factors that could be costing the United States $1 trillion. This includes costs related to overtreatment and unnecessary treatments, bloated administrative structures, fraud and overspending that result from an inability to effectively shop for best price. These gaps, failings and their corresponding enormities are an entrepreneurs and investors dream.

At its core, medicine is about gathering, deciphering and sharing information; information flows between patients and doctors, doctors and doctors, doctors and pharmacists, and so forth. This stream of facts, figures, and experiences ultimately results in the care of a patient.

Thanks to the transformative technologies weve seen in this young century, a transformation in the processing and dissemination of information has taken place, with more knowledge at our fingertips than imaginable just a few decades ago. From globe-spanning social connections to seemingly infinite encyclopedias to mobile connectivity and computing, several quantum leaps forward in technological capabilities now enable forward-thinkers to create a new world where price transparency and seamless collaboration are the norm.

Yet, despite the enormous advances in processing power and capability over the last 50 to 100 years, there remain many aspects of the actual process of practicing medicine that have barely evolved. While machines are unlikely to completely replace doctors anytime soon (or ever), the fact remains that there are a number of areas where the accurate, timely processing of information can dramatically improve patient well-being and ultimately the quality, cost and accessibility of both basic and complex healthcare.

Areas, like streamlining administrative processes, reducing redundancy or unnecessary procedures, or facilitating early and frequent interaction with medical professionals to treat conditions early or prevent them in the first place, are ripe for disruption from innovative approaches driven by technology. Investments in the following four categories are among the most obvious, lucrative and mutually advantageous areas where transformational change is possible and needed.

Medical Records: When you think about it, health records are actually incredibly inefficient. Not only do you have to fill out comprehensive medical questionnaires by handyou have to repeat this process every time you change doctors, switch insurance companies, or alter your records in any way. Not only is this a colossal waste of time, but I shudder to think of the details that are mistaken or forgotten and how that might impact optimal care.

Its not unreasonable to expect that, in todays digital age, ones health records should not only be easily accessible but also reside with the individual rather than being dispersed among the countless healthcare providers that the person is involved with. For too long, healthcare providers have been overly protective of this information often to the detriment of the patient. While some strides have been made in this area, substantial work remains to be done to create true interoperability among providers for a specific patient.

This efficiency will improve the process of caring for a patient and in many cases will improve outcomes because doctors will always instantly have comprehensive information at their fingertips. Medical histories, treatment plans or idiosyncratic issues will no longer slip through the cracks. The scope of this issue is highlighted when considering patients dealing with multiple complex issues that might involve numerous specialists and general practitioners. Moreover, a patients health record shouldnt be just for the provider, it should be user-friendly so that the patients themselves can monitor and manage their health.

Big players in tech are already making strides towards filling this customer service void, but the big gamechanger in this field still has yet to present itself. Its a completely realistic expectation that within the next decade well have moved onto quick, convenient, and secure medical records. There likely will be many players enabling the gathering, managing and sharing of patient information; however, the real transformational change will occur when the data contained in the health record is used to proactively diagnose and treat patients.

The Delivery of Care: Traditionally, the doctors office or hospitals was where medicine was almost exclusively practiced. Today, technology is enabling care for many basic issues to be delivered remotely to wherever the patient is. Telemedicine, or virtual care, utilizes technology so that doctors can seamlessly and, in some cases, instantly connect with patients to deliver care on demand.

The first iteration of this approach is traditional telemedicine, which uses video conferencing or a phone call to connect a doctor and patient. This approach is quickly and not unsurprisingly being usurped by asynchronous text on a smartphone how the world prefers to communicate where the doctors capabilities are being augmented by deep technology and AI. Providing easy and true on-demand accessibility for patients enables them to be treated early and often, which will unquestionably improve health outcomes. Pairing physicians with leading-edge technology can generate substantial efficiencies and leverage that, in turn, will reduce costs, increase quality and substantially expand those covered.

The flu offers a simple illustration of the power of technology that allows on-demand, remote care delivery: At the onset of symptoms, a patient can engage with a doctor and receive treatment. Instead of juggling their schedules or waiting to see a doctor which averages 29 days according to a Merritt Hawkins 2017 study the disease is treated promptly before it gets too far along. Furthermore, this remote treatment dramatically reduces contamination because there is no sitting in a waiting room or traveling often on mass transit to visit a doctor or urgent care center. In this scenario, everyone patient, provider, community and employer wins.

Similarly, technology is transforming how a patient is monitored either following a procedure or for chronic issues. In many cases, vital statistics can be monitored remotely and transmitted instantly to a care team. This enables patients to recover at home, which is more comfortable, cheaper, and comes without the infectious risks present at a hospital. For patients with chronic diseases, the ability to easily and accurately monitor factors like blood glucose levels, heart rate or blood pressure can be transformative in terms of managing a disease or preventing problems down the road. On a related note, technology-based tools can be employed to aid and ensure prescription adherence, which currently poses a huge and unnecessary cost to the system.

Healthcare delivery is only beginning to embrace the power of technology especially that of a smartphone to cut costs, increase access and improve quality. As I previously wrote, I believe that the power and ubiquity of smartphones will improve the worlds health on an individual and collective basis. Virtually every other aspect of our lives have been enhanced by this technology with the exception of primary healthcare.

Clinical Decision Support: The capabilities of AI, machine learning and big data can be applied to many aspects of healthcare in order to leverage a doctors time, improve quality and drive much needed efficiencies. Deep technology can now review images and tests faster and often more accurately than humans. The sheer mass and dispersion of medical information and current research makes it virtually impossible for a single doctor to always be up to speed. Technology that can foster the analysis and sharing of vast and complicated information will give doctors instant access to the plethora of research studies and clinical trials that might be relevant to their patients. Using technology to quickly and accurately identify and process information on a clients behalf will only improve care and drive down costs.

Precision Medicine / Personalized Diagnoses: Given the powerful computers at our disposal, it is easy to envision how we could use computers to aid decision-making, plugging in numerous permutations, conditions, and individual attributes unique to patients in order to determine the problems at hand and the optimal treatment plan. For example, for a prescription one will no longer need to rely on the catch all adult dosage and can instead determine the best amount for each patient based on their unique composition and metabolism.

Personalizing diagnoses is where AI is beginning to show real promise. Researchers have developed the technology for identifying heart disease, lung cancer and eye maladies with machine learning, and theyre only getting started. Even more cutting-edge is where a patients genome is analyzed to determine precisely the diagnosis and corresponding treatment plan. This capability is still in its infancy and only possible due to the advancements and price reductions in computing power.

Healthcare is ripe for the benefits technology affords and, as the responses and capabilities relating to Covid-19 demonstrates, desperately needs an update. Relative to other areas, I think the aforementioned categories might be low hanging fruit and hence represent significant investment potential. What I find particularly exciting is that the space is so large and in such desperate need that there will be a wide array of places to invest with potentially several players in each area. Fields such as Artificial Intelligence, Data Management and Cloud Computing offer much promise when applied to healthcare, especially in disrupting several areas that suffer from stagnation and lack of development. These applications will benefit doctors and patients alike while concurrently offering very attractive returns to the investors and entrepreneurs behind the companies. Lastly, and equally compelling, is that an investment that helps improve healthcare provides a greater good by enhancing lives and benefiting communities.

Photo: JamesBrey, Getty Images

Go here to see the original:
Is there a better market to invest in than healthcare? - MedCity News

DUBLIN, April 6, 2020 /PRNewswire/ -- The "Global Minimally Invasive Biopsy Technologies Market: Focus on Liquid Biopsy, Optical Biopsy, and Brush Biopsy, Pigmented Lesion Assays, and Breath Biopsy, Regulatory Scenario, Therapeutic Application, Competitive Landscape,18 Countries' Data - Analysis and Forecast, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

According to the report, the global minimally invasive biopsy technologies market was valued at $924.8 million in 2018 and is anticipated to reach $4.03 billion by 2030. The global minimally invasive biopsy technologies market is expected to grow at a double-digit compound annual growth rate (CAGR) in the forecast period 2019-2030, aided primarily by the anticipated launch of novel minimally invasive biopsy technologies.

The rapidly growing incidences of cancer and other chronic inflammatory disorders are inciting the use of minimally invasive and real-time diagnostic methods for early detection. With better patient compliance and greater sensitivity, minimally invasive biopsy technologies such as liquid biopsy and optical biopsy are emerging as novel tools for the early detection and effective disease management. Additionally, several other technologies including brush biopsy, fine needle aspiration, breath biopsy, and pigmented lesion assays are considerably evolving to be used in the minimally invasive management of cancer.

The increasing adoption of targeted therapies and the growing prominence of the concept of personalized medicine is driving the adoption of minimally invasive biopsy technologies. The increasing adoption is further expected to bring down the cost and is expected to improve the patient access to these technologies.

North America is the leading contributor in the global minimally invasive biopsy technologies market and contributed approximately 62.06% to the global market value in 2018. This region is anticipated to grow at a CAGR of 11.25% during the forecast period 2019-2030 and to continue dominating the global market in 2030 as well. However, the European region is expected to grow at an impressive CAGR of 15.40% during the forecast period 2019-2030. The Asia-Pacific region contributed a share of 12.41% to the global market and is anticipated to grow at a CAGR of 14.65% during the forecast period 2019-2030.

Research Highlights

Optical biopsy expected to witness an impressive CAGR of 15.77% during the forecast period 2019-2030. Moreover, in terms of therapeutic application, prostate cancer is expected to witness an impressive growth at a CAGR of 14.97% during the forecast period 2019-2030.

Liquid biopsy is currently the largest shareholder in the global minimally invasive biopsy technologies market. This market dominance is largely attributed to the worldwide availability of a significant number of liquid biopsy technologies.

This market intelligence report provides a multi-dimensional view of the global minimally invasive biopsy technologies market in terms of market size and growth potential. This research report aims at answering various aspects of the global minimally invasive biopsy technologies market with the help of key factors driving the market, restraints that can possibly inhibit the overall growth of the market, and the current growth opportunities that are going to shape the future trajectory of the market expansion.

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches and approvals, partnerships, collaborations, business expansions, as well as mergers and acquisitions. The research report provides a comprehensive analysis of the product sales, manufacturers, service providers, and trend analysis by segment, and growth share analysis by region. Additionally, the report provides a comprehensive attractive analysis and opportunity analysis for the entire global minimally invasive biopsy technologies market for 2018 and 2030.

This report is a meticulous compilation of the research of about 65 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of 9 leading companies, market participants, and vendors. The report also comprises 15 detailed company profiles including that of Abcodia Ltd., Adaptive Biotechnologies, Biocept, Inc., Caliber Imaging & Diagnostics, Chronix Biomedical, DermTech, F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Mauna Kea Technologies, Myriad Genetics, NeoGenomics Laboratories, Inc., Owlstone Medical Ltd, QIAGEN, Thermo Fisher Scientific, and Veracyte, Inc.

The answers to the following key questions can be derived from this report:

Key Topics Covered

Executive Summary

1 Product Definition1.1 Inclusions and Exclusions

2 Research Scope2.1 Scope of Work2.2 Key Questions Answered in the Report

3 Research Methodology3.1 Global Minimally Invasive Biopsy Technologies Market: Research Methodology3.1.1 Primary Data Sources3.1.2 Secondary Data Sources3.1.3 Selection Criteria for Company Profiles

4 Industry Analysis4.1 Industry Ecosystem4.2 Regulatory Framework and Government Initiatives4.2.1 Liquid Biopsy: Regulatory Framework4.2.1.1 Liquid Biopsy: Regulations in the U.S.4.2.1.2 Liquid Biopsy: Regulations in Other Countries4.2.2 Optical Biopsy and Other Technologies: Regulatory Framework4.2.2.1 Optical Biopsy and Other Technologies: Regulations in the U.S.4.2.2.2 Optical Biopsy and Other Technologies: Regulations in Europe4.2.2.3 Optical Biopsy and Other Technologies: Regulations in Other Countries4.3 Patent Analysis4.3.1 Liquid Biopsy: Patent Analysis4.3.2 Optical Biopsy: Patent Analysis4.4 Physician's Perception

5 Competitive Landscape5.1 Key strategies and Developments5.1.1 Partnerships, Alliances, and Business Expansions5.1.2 New Offerings5.1.3 Funding Activities5.1.4 Procurement and Sales Agreements5.1.5 Regulatory and Legal Developments5.1.6 Mergers and Acquisitions5.2 Market Share Analysis5.2.1 Market Share Analysis: Global Liquid Biopsy Market5.2.2 Market Share Analysis: Global Optical Biopsy Market5.2.3 Market Share Analysis: Global Other Technologies Market5.3 Growth Share Analysis5.3.1 Growth Share Matrix (by Technology)5.3.2 Growth Share Matrix (by Therapeutic Application)5.3.3 Growth Share Matrix (by Region)

6 Global Minimally Invasive Biopsy Technologies Market, 2018-20306.1 Assumptions and Limitations6.2 Key Findings and Opportunity Assessment6.3 Global Minimally Invasive Biopsy Technologies, Market Scenario6.3.1 Global Minimally Invasive Biopsy Technologies Market Size and Forecast (2018-2030)6.3.2 Market Dynamics6.3.2.1 Overview6.3.2.2 Impact Analysis6.3.2.3 Market Drivers6.3.2.3.1 Rising Global Burden of Cancer6.3.2.3.2 Increasing Number of Cross-Industry Collaborations6.3.2.3.3 Growing Prominence of Precision Medicine6.3.2.4 Market Restraints6.3.2.4.1 Uncertain Regulatory Requirements6.3.2.4.2 Lack of Favorable Reimbursement Policies6.3.2.4.3 Technical Challenges Associated with the Analysis of Circulating Biomarkers6.3.2.5 Market Opportunities6.3.2.5.1 Business Expansion in Emerging Economies6.3.2.5.2 Integration of Artificial Intelligence (AI)6.3.2.5.3 Rising Number of Initiatives by the Government6.4 Market Estimation Method

7 Global Minimally Invasive Biopsy Technologies Market, by Technology, 2018-20307.1 Overview7.2 Global Liquid Biopsy Market Scenario, 2018-20307.2.1 Principle and Advantages of Liquid Biopsy7.2.2 Key Findings and Opportunity Assessment7.2.3 Global Liquid Biopsy Market, Market Size and Forecast (2018-2030)7.2.3.1 Market Dynamics7.2.3.1.1 Impact Analysis7.2.3.1.2 Market Drivers7.2.3.1.2.1 Increasing Demand for Liquid Biopsy Tests7.2.3.1.2.2 Recent Product Launches and Approvals7.2.3.1.2.3 Strong Pipeline7.2.3.1.3 Market Restraints7.2.3.1.3.1 Uncertain Regulatory Requirements7.2.3.1.3.2 Lack of Adequate Reimbursement7.2.4 Global Liquid Biopsy Market Segmentation7.2.4.1 Global Liquid Biopsy Market (by Product), 2018-20307.2.4.1.1 Overview7.2.4.1.2 Tests7.2.4.1.3 Kits and Consumables7.2.4.1.4 Instruments7.2.4.2 Global Liquid Biopsy Market, by Circulating Biomarker, Market Size and Forecast (2018-2030)7.2.4.2.1 Overview7.2.4.2.2 Circulating Tumor DNA (ctDNA)7.2.4.2.3 Circulating Tumor Cells (CTCs)7.2.4.2.4 Cell-Free DNA (cfDNA)7.2.4.2.5 Extracellular Vesicles and Others7.2.4.3 Global Liquid Biopsy Market, by Clinical Application, Market Size and Forecast (2018-2030)7.2.4.3.1 Overview7.2.4.3.2 Treatment Monitoring7.2.4.3.3 Prognosis and Recurrence Monitoring7.2.4.3.4 Treatment Selection7.2.4.3.5 Diagnosis and Screening7.2.4.4 Global Liquid Biopsy Market, by Therapeutic Application, Market Size and Forecast (2018-2030)7.2.4.4.1 Overview7.2.4.4.2 Lung Cancer7.2.4.4.3 Breast Cancer7.2.4.4.4 Prostate Cancer7.2.4.4.5 Colorectal Cancer7.2.4.4.6 Blood Cancer7.2.4.4.7 Other Types of Cancer7.2.4.4.8 Non-Oncology Applications7.3 Global Optical Biopsy Market Scenario, 2018-20307.3.1 Principle and Advantages of Optical Biopsy7.3.2 Key Findings and Opportunity Assessment7.3.3 Global Optical Biopsy Market, Market Size and Forecast (2018-2030)7.3.3.1 Market Dynamics7.3.3.1.1 Impact Analysis7.3.3.1.2 Market Drivers7.3.3.1.2.1 Recent Product Launches and Approvals7.3.3.1.2.2 Significant Number of Funding and Investments7.3.3.1.2.3 Anticipated Product Launches7.3.3.1.3 Market Restraints7.3.3.1.3.1 Lack of Favorable Reimbursement7.3.3.1.3.2 Stringent Regulatory Guidelines7.3.4 Global Optical Biopsy Market (by Therapeutic Application), 2018-20307.3.4.1 Overview7.3.4.2 Oncology7.3.4.3 Non-Oncology Applications7.4 Global Other Technologies Market Scenario, 2018-20307.4.1 Overview7.4.2 Key Findings and Opportunity Assessment7.4.3 Global Other Technologies Market, Market Size and Forecast (2018-2030)7.4.3.1 Market Dynamics7.4.3.1.1 Impact Analysis7.4.3.1.2 Market Drivers7.4.3.1.2.1 Ongoing Strategic Collaborations and M&A Activities7.4.3.1.2.2 Strong Product Pipeline7.4.3.1.3 Market Restraints7.4.3.1.3.1 Poor Reimbursement Scenario7.4.3.1.3.2 Limited Scope of Expansion in Emerging Economies7.4.4 Global Other Technologies Market, (by Therapeutic Application)7.4.4.1 Overview7.4.4.2 Lung Cancer7.4.4.3 Melanoma7.4.4.4 Thyroid Cancer7.4.4.5 Non-Oncology Applications

8 Global Minimally Invasive Biopsy Technologies Market, (by Region), 2018-20308.1 Overview and Key Findings8.2 North America8.3 Europe8.4 Asia-Pacific8.5 Latin America and the Middle East8.6 Rest-of-the-World

9 Company Profiles9.1 Abcodia Ltd.9.2 Adaptive Biotechnologies9.3 Biocept, Inc.9.4 Caliber Imaging & Diagnostics9.5 Chronix Biomedical9.6 DermTech9.7 F. Hoffmann-La Roche Ltd.9.8 Guardant Health, Inc.9.9 Mauna Kea Technologies9.10 Myriad Genetics9.11 NeoGenomics Laboratories, Inc.9.12 Owlstone Medical Ltd.9.13 QIAGEN9.14 Thermo Fisher Scientific9.15 Veracyte, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/3128v2

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-minimally-invasive-biopsy-technologies-markets-2019-2030---a-4-billion-opportunity-with-focus-on-liquid-biopsy-optical-biopsy-and-brush-biopsy-pigmented-lesion-assays-and-breath-biopsy-301035982.html

SOURCE Research and Markets

Read more:
Global Minimally Invasive Biopsy Technologies Markets, 2019-2030 - A $4+ Billion Opportunity with Focus on Liquid Biopsy, Optical Biopsy, and Brush...

Heading into this year, I was passionate about getting a very important message in front of investors.

Source: Shutterstock

It was my thesis that the next decade would not only be the most innovative in history, but that the stock market would experience its largest gains ever.

The start of 2020 as brutal as it has been reminds me of 1990. Stocks had already been in a bull market for eight years when the ball dropped on 1989 and ushered in the new decade. Most experts believed the bull market was over and that the 1990s would be a lost decade.

Boy, were they wrong.

The 1990s went on to become one of the greatest decades for stocks. Little technology companies youd never heard of became household names. Dell Computer now Dell Technologies (NYSE:DELL) gained over 91,000% during the 1990s. The biggest gains of the decade were driven by a plethora of new technologies centered around the internet and personal computing.

Today, we are now three months into the 2020s and stocks are in a similar situation. We entered the decade on the back of a 10-year bull market, only to slide quickly into a bear market.

Most people dont realize this, but the Dow did something similar in 1990. It fell by 19.5% essentially a bear market to start the decade before powering higher. I believe we will look back at the current sell-off and see it as the last great buying opportunity before a booming decade.

The selling is creating buying opportunities in investment trends that wont slow due to the pandemic. In fact, they could even accelerate due to the changing global landscape. Lets take a look at a few

Robotics:According to the editorial board atScience Robotics, robots could be an alternative to humans when it comes to certain healthcare tasks. Especially during a pandemic. Robots could collect lab results, automate lab tests, and help disinfect the patient rooms. In China, it was deemed too dangerous for humans to make critical deliveries of medicine and food into infected areas, so the country turned to robots.

Genomics:The future of healthcare will be based on advances in both technology and medicine. The latter will rely on the field of genomics. In the coming decade, it will be the norm to have your genome sequenced. This information will help create personalized medicine for each patient, as well as help speed up the creation of new drugs.

The response to the coronavirus is a great example of how medicine is evolving. In 10 years, this type of pandemic would not be an issue. The combination of artificial intelligence (AI), quantum computing, and genomics would create a vaccine within days.

Tele-everything:The biggest change to our lives throughout this ordeal has been the self-isolation. Either through a government mandate or by choice, most people around the globe are staying inside and not going about their normal activities. This has led to a work-from-home, school-from-home, and even workout-from-home situation.

The companies behind this trend are here to stay. When the pandemic is over, people will go back to work, school, and their local fitness facilities. But the tele-everything trend is not going away. In some circumstances, it is more convenient than what we were accustomed to. Everything from software companies to one of my favorite stocks,Teladoc (NYSE:TDOC), to online education will be pushed to grow faster and quicker after the pandemic.

Even though a lot of the stocks in these trends have been beaten down in the last month, the trends themselves are not dead. Nothing I mean nothing in life goes straight up. When it comes to the stock market, the strongest trends will hit speed bumps but those bumps offer investors opportunities.

Let me be straight with you. If you want to be wealthy, you must buy into high-growth, long-term trends. And to make the BIG money you need to buy when everyone else is selling.

That day is today.

Matthew McCall left Wall Street to actually help investors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. The power of being first gave Matts readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities.

More:
3 High-Growth Trends to Invest In Now - Investorplace.com

The current pandemic situation that the world is suffering due to the SARS-CoV-2 coronavirus is hopelessly transforming any forecast that would have been set for 2020 in most environments. Even more in the field of health, where efforts are being made to end this situation.

In the case of personalized medicine in Spain, this year they expected to solve technological, social, legal, ethical and healthcare challenges with the possible approval of a strategic plan by the Government, which has been analyzed by the Senate for more than two years with the collaboration of experts in the field. A long-awaited regulation that it is more than likely to delay again.

From the point of view of the investigation, advances were outlined in CRISPR / Cas9, a molecular tool to edit or correct the genome of a cell. Also in a more efficient and combined use of the so-called micas omics sciences: genomics, metabolomics, epigenomics, etc., which, even though they have been going for several years, are still at the dawn of their journey.

Companies like OncoDNA, a company specialized in precision medicine for the treatment and diagnosis of cancer, continue working to promote new advances in this last section. She has spent several years dedicated to carrying out genomic analysis of samples from cancer patients, tissue and blood (liquid biopsy), to offer more information on the genetic profile of each tumor to specialists and thus be able to determine the most appropriate therapy for the patient.

Over the past 12 months the number of genes analyzed has been expanded in their tests, arriving their OncoDEEP and OncoSTRAT & GO solid biopsy panels until 313 and even, combining tissue analysis with liquid biopsy in stage IV solid tumors. Incorporating new essential biomarkers to know the peculiarities that can occur in each patient.

Pending all the news

In the same way, researchers continue to be very aware of the different publications that are appearing in the most prestigious media in the world in the field of oncology to improve their services. An example of this were the changes adopted a few months ago in your OncoSTRAT & GO test.

This new version includes the study of germline mutations in the ATM, BRCA1 and BRCA2 genes, as well as other pathway genes involved in homologous recombination, which can also be treated with PARP inhibitors. A solution that is already available and that is especially useful in patients with ovarian, prostate, pancreas and triple negative breast cancer.

In laboratories, and with the collaboration of different hospitals and specialized cancer centers around the world, work is also being done on this combination of omics sciences, which could offer a much more individualized view of the molecular profile of each patient, thus improving their prospects of success against cancer. Even to turn them into an effective tool to predict and assume preventive intervention strategies.

More advances in big data

Processing large amounts of data it will also continue to be key in the field of personalized medicine. Increasingly, taking into account that the progressive evolution of the micas omics will require technologies that translate their results into a language understandable to healthcare professionals.

In the oncological case they begin to emerge computer applications capable of processing and translating in a very short time the large amount of genetic information that each genomic analysis offers us. As with OncoKDM, an intelligent online genomic interpretation platform that responds to the most immediate needs of oncologists, pathologists, and other specialists in molecular biology.

It is capable of bringing together all the information that has been collected about a patient, such as the results of any genomic technology, molecular pathology data or clinical information, analyzing and interpreting it effectively at a clinical and biological level in a few minutes. In this way, it facilitates the oncologists decision making when choosing the ideal therapy for the patient or searching for clinical trials available in their country of origin , explains Adriana Terrdez, director of OncoDNA in Spain and Portugal.

It is to be expected that solutions such as those of genomic tests or software and platforms for the processing and interpretation of genomic data continue to evolve in the future in order to improve cancer patient care and make the best decisions in each case. It is working day by day in order that the news arrive as soon as possible. Even in these uncertain times.

//

Visit link:
COVID-19 transforms the challenges of Personalized Medicine for 2020 - Explica

According to a new report published by Proficient Market, titled, Global Biochip Market by Product Type (DNA Chips Market, Lab-On-A-Chip Market, Protein Chips Market & other) and by End-Users/Application (Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostics Centers, Academic & Research Institutes & Other) Global Market Share, Forecast Data, In-Depth Analysis, and Detailed Overview, and Forecast, 2015 2027 The report has offered an all-inclusive analysis of the global biochip market taking into consideration all the crucial aspects like growth factors, constraints, market developments, top investment pockets, future prospects, and trends. At the start, the report lays emphasis on the key trends and opportunities that may emerge in the near future and positively impact the overall industry growth.

According to the report, Global Biochip Market in 2019 stood at USD 14 billion and is expected to reach USD 62.82 billion by 2027 growing at a CAGR of 20.63% from 2020 to 2027.

Get Free Sample PDF (including full TOC, Tables and Figures) of Biochip Market @ https://proficientmarket.com/sample/1183

A biochip is a collection of microarrays organized on a solid substrate, allowing thousands of complex biochemical reactions, to determine various biological data, for instance, decoding the genes in less time. The biochip-based analysis is primarily used for on-site diagnosis. Biochips also undergo other diagnostic applications such as microarray technique, microfluidic technologies, & biosensors. A biochip can also provide analytical data regarding organic molecules associated with the living organisms. It helps in identifying airborne toxins, environmental pollutants, gene sequences, & other biochemical constituents.

Biochip Market Key Players: The research study includes profiles of leading companies operating in the global biochip market. Key players profiled in the report include:

Abbott Laboratories Agilent Technologies PerkinElmer Inc. Fluidigm Corporation Illumina GE Healthcare Bio-Rad Laboratories Inc. Cepheid Inc. Thermo Fisher Scientific F. Hoffmann-La Roche AG.

Do enquire to get a strategic overview of the market, Access Research Methodology Prepared By Experts at: https://proficientmarket.com/buying-request/1183

Thermo Fisher Scientific Inc. completed the acquisition of Affymetrix Inc., a leading provider of cellular and genetic analysis products. This acquisition helped Thermo Fisher to strengthen its leadership in biosciences, as well as acquire new genetic analysis capabilities to better serve clinical and applied markets.

Drivers for the Global Biochip Market: The increased use of biochips due to increasing cancer treatment and diagnostics. Rise in personalized medicine, drug discovery and life science research, need for high speed diagnostics and increased government funding are some of the key factors driving the growth for global biochips market. In addition, increasing healthcare awareness is also fueling the growth of global biochips market. Thus all these factors led to boosting the growth of the biochips market.

Opportunities for the Global Biochip Market: Rapid growing application of biochips will drive the market growth during forecasted period. While the Technological advancements and new product launches in the market are witnessed to augment the growth of the biochips market in forthcoming years. However, Rising demand of biochips in developing countries is witnessed to increase the market share of biochips. Moreover the Increasing adoption of personalized medicines by households will also propel the growth of the biochips market. Thus, all these factors will provide lucrative opportunities for the growth of the biochips market.

Restrains for the Global Biochip Market: The Strict government regulatory guidelines related to biochips are hampering the growth of the market. While the High instrument costs will also restrain the growth of this market. Lack of proper knowledge about biochip technology is a prominent restraint lowering the demand for biochip products. The irregularities arriving in healthcare coverage around the world are also more likely to challenge the growth of biochips market. Variable cost and adoption of biochip technologies is likely to affect the personalisation of medicine, eventually lowering the revenues of the global biochips market. Thus all these factors are creating a negative impact at the growth of the biochip market.

Region Wise, Global Biochip Market Analysis: Report covers the region wise analysis, global Biochip market can be segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Among all, North America leads the global Biochip market share followed by Europe and Asia Pacific. While the North America leads the global Biochip market due to the factors such as presence of well-established players, advanced informatics infrastructure, presence of experts and skilled workforce, and ongoing genomic R & D practices on a large scale in the region. While the rising R & D investments in genomic research is driving the growth of the market. Moreover, growing awareness regarding genetic tests for disease risk assessment and prevention is anticipated to have a positive impact on the growth of the regional market..

Access Full Report, here: https://proficientmarket.com/report/1183/global-biochip-market

Global Biochip Market: Product analysisDNA Chips MarketGene ExpressionSNP GenotypingCancer Diagnosis & TreatmentGenomicsDrug DiscoveryAgricultural BiotechnologyLab-On-A-Chip MarketClinical DiagnosticsGenomicsIVD & POCProteomicsDrug DiscoveryProtein Chips MarketProteomicsExpression ProfilingDiagnosticsHigh-Throughput ScreeningDrug DiscoveryOther Cell ArraysTissue Arrays

On the basis of type DNA Chips Market, accounted for largest share of total revenue generated due to the increasing use of DNA chip products. The use of DNA chip has empowered the scientific community by enabling measurement of the expression levels of large numbers of genes simultaneously. A DNA chip involves an array of microscopic spots each carrying numerous single-stranded oligonucleotides and are widely being used in biomedical research activities. Thus due to its huge utilization led to the growth of this segment which is fueling the biochip market.

Global Biochip Market: Application analysisBiotechnology and Pharmaceutical CompaniesHospitals and Diagnostics CentersAcademic & Research InstitutesOther

The demand of Global Biochip Market is highest from Biotechnology and Pharmaceutical Companies due to the numerous features offered by it. The utilization rate of biochips in biotechnology and pharmaceutical companies was high. The hospitals & diagnostics is the second fastest growing segment due to the adoption of biochip in new drug discovery as well as in point-of-care diagnostics has increased the consumption of these biochips in hospitals & diagnostics centers. Thus all these factors led to increase usage of biochips in this sectors which is propelling the growth of the biochip market.

Global Biochip Market: Region analysisNorth America: U.S., Canada, MexicoEurope: U.K., France, Germany, Spain, Italy, Rest of EuropeAsia Pacific: China, Japan, South Korea, ASEAN, IndiaRest of Asia Pacific: Latin America, Brazil, Argentina, Colombia, Rest of L.A.Middle East and Africa: Turkey, GCC, UAE, South Africa, Rest of Middle East

The report can be customized as per client requirements. For further queries, you can contact us on [emailprotected] or +1-773-800-2974. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Read the full press release and latest news of this report, here: https://proficientmarket.com/press-release/1188/global-biochip-market

About Us:Proficient Market is the leading research company offering both tactical and strategic support to all our customers. Customer satisfaction is our goal and that is why, we have a team of skilled and experienced specialists with the ability to do data mining, information management, and revenue enhancement solutions to ensure that our clients make informed decisions when coming to investing in the market. Our happiness is when we help our clients grow their business, strengthen the brands and educate their members or consumers through the ever-new fun research methods developed by our team.

Contact Us:Proficient Market1st Floor, Harikrishna Building,Samarth Nagar, New Sanghvi,Pune- 411027 IndiaTel: +91-8149441100 (GMT Office Hours)USA: +17738002974Email: [emailprotected]Web: proficientmarket.com

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at [emailprotected].

WiredRelease

Visit WiredRelease's Website

Here is the original post:
Insights On The Global Biochip Market To 2027 Featuring Abbott Laboratories, Agilent Technologies, PerkinElmer Inc., Fluidigm Corporation, Illumina,...

Technological advancements and scientific breakthroughs have propelled the assessment of pathogenesis and fostered precision medicine industry. Precision medicine has become instrumental in alleviating suffering pertaining to medical care, owing to unintended side effects resulting from one-size-fits-all approach.

Rapid transformation towards precision medicine is also believed to reduce the cost of treatment by doing away with inapt treatment plans. Precision medicine has become pivotal in leveraging doctors to select treatments based on a genetic understanding of the patient's disease and creating a personalized treatment plan.

Genetic laboratory industry is believed to be using processing power, data, science and operators to enhance the results for costly and debilitating diseases. In terms of technology, big data is touted to set the trend in precision medicine market as the technology enables more precision and tailoring compared to linking diverse data sets to showcase casual pathways. Dependence of precision medicine on big data has propelled the biomedical research.

Request sample copy of this report @ https://www.decresearch.com/request-sample/detail/671

Stakeholders have shown increased traction towards big data analytics for it complements clinical care and streamlines public health surveillance. Notably, big data has the ability to track and predict major outbreaks to boost public healthcare resources and disseminate healthcare message to patients using social media.

Profound deployment of sensing technologies has fared well for big data analytics. With soaring trend for implantable and wearing sensing has been in line with the increased bandwidth and improved microelectronics.

With the wealth of information to different disease, big data revolution has offered an opportunity to embrace AI and machine learning algorithms in the massive data set. Global Market Insights, Inc., predicts big data analytics market share to have been registered at 12% in 2019, citing influx of complex of data generating in healthcare sector.

Make Inquiry about this report @ https://www.decresearch.com/inquiry-before-buying/671

Recent advancements in technology indicate that stakeholders are increasingly using precision medicine in oncology. With neurological disorders being one of the leading causes of morbidity and disability globally, precision medicine has grown in significance. The disorder is expected to grow on the heels of increased life expectancy and population growth leading to economic burden and health issues.

Oncology has opened avenues for precision medicines as central nervous system (CNS) market share in 2019 was pegged at over 24%, mainly attributed to soaring prevalence of CNS disorders globally.

Use of precision medicine in healthcare IT companies will become more noticeable in the next five years owing to soaring demand for technologically advanced equipment for analysis, rapid integration and storage of patient data. In bid to push to the capabilities in data analysis, data acquisition, and analytics-based decision making, established technology players and startups are adopting precision medicine.

Several healthcare IT companies are offering operation and software tools for healthcare systems to adopt personalized medicine. Healthcare IT companies segment was pegged at around US$ 16 bn in 2019.

With the time ideal for disruption through strategic business model owing to changing healthcare dynamics, stakeholders are increasingly inclined towards infusing investment in MEA. Leading companies believe MEA to emerge as a prominent growth ground for the industry.

While massive data has been captured for advanced economies, dearth of data in African countries and most of the Gulf countries has signified the importance of precision medicine. Further, burgeoning population has also been one of the factors fueling growth in the region. MEA market was pegged at over USD 3.0 billion in 2019 and is estimated to expand at a CAGR of more than 10.0% during the forecast period.

View original post here:
Precision Medicine Market growth outlook with industry review and forecasts - GroundAlerts.com

object(stdClass)#31465 (59) { ["id"]=> string(4) "5792" ["title"]=> string(69) "How Blockchain Improves Logistics: Benefits, Drawbacks, and Use Cases" ["alias"]=> string(66) "how-blockchain-improves-logistics-benefits-drawbacks-and-use-cases" ["introtext"]=> string(177) "

The blockchain technology and logistics industry tend to be quite profitable for each other. Additionally, this collaboration brings benefits to carriers and customers.

In this article, well discuss all you need to know about blockchain in the logistics sector.

Blockchain allows optimizing logistic processes in the real-time mode. This technology tends to improve the relationship between shippers and carriers.

We've singled out six main advantages of using blockchain in the logistics sector. Lets discuss them more precisely.

There are a lot of documents required for the transportation process. For example, a bill of lading or B/L. It stands for an agreement that consists of transportation terms, conditions, and other issues.

Blockchain allows recording all the steps. As a result, any participant can look through the delivery chain. If something happens, recorded information will report a problem.

Blockchain allows optimizing routes and delivering faster. In this case, smaller companies can compete with bigger ones, offering faster routes.

As a result, its possible to reduce expenses on the shipping process.

Blockchain simplified the process of goods certification. The combination of IoT and blockchain allows creating smart contracts.

Transactions made on blockchain are secure. Its impossible to change something in the transaction. It leads to decreasing fraudulent operations.

Intermediaries stand for agents that take part in the transportation chain. However, withlogistics software development, the industry doesnt need such specialists.

Weve already mentioned smart contracts. They tend to reduce time and expenses. Also, both parties have an opportunity to automate the validation process, manage obligations, and so on.

There were main blockchain advantages. As you can see, this technology can be quite profitable for the logistics industry.

Of course, there are some disadvantages of using blockchain technology. Lets discuss them more precisely.

Blockchain allows automating supply processes. As a result, there is no need for various specialists. The number of unemployed workers will rise.

Businesses that use blockchain technology should have a standard process. Unfortunately, these days, businesses dont have one.

Its required to create a standard process on the government level. So, businesses can follow it to avoid some common problems.

Its evident that blockchain development is expensive and time-consuming. Additionally, its required to have powerful hardware.

Also, there are expenses on specialists that are experienced in blockchain integration.

So, blockchain is a quite expensive technology that requires additional preparation before using it. However, some companies have already integrated blockchain and got some profit.

Blockchain makes it easy to track goods during shipment. Additionally, the companies have an opportunity to monitor the conditions of the packages.

As a result, its possible to detect broken goods, spoilt products, and so on.

Of course, such opportunities lead to decreasing unnecessary expenditures.

Successful story. Walmart cooperates with IBM to use the blockchain technology in the logistics. The system allows seeing what products are sold. Also, its possible to know the location of the product (the particular warehouse). The company claims that the supply process becomes more transparent.

Blockchain allows reducing the number of documents required for transportation. Additionally, the number of mistakes will also decrease due to automatization. The shipping terms fulfill more precisely.

Let's face it payments are important for any business. Blockchain makes this process secure. For example, its possible to make transactions with such cryptocurrencies as Bitcoin. As a result, the payment process is secure and transparent. Also, such solutions improve international processes.

Successful story. Tallysticks has made a platform that simplified payment processes using blockchain. The solution offers smart contracts that can be customized depending on the business needs and requirements.

Blockchain gives end consumers an opportunity to simplify the authenticity of the goods. There are platforms with data about product origin, quality, fineness, and others.

This technology gives clients transparency. As a result, people trust companies more.

Blockchain makes cooperation easier. For example, enterprises can cooperate with small companies to deliver goods faster. Such a solution is profitable for both parties.

These days, companies can cooperate with each other without intermediaries. It leads to cost reduction and improved delivery processes.

Successful story. ShipChain platform uses blockchain to improve cooperation. For instance, the service allows tracking the delivery from the warehouse to the buyer's door. It leads to better customer experience and satisfaction.

The delivery process is long and expensive. Also, there can occur various delays due to weather conditions and other issues.

Usually, to manage such issues, companies hire lawyers. However, blockchain changes the situation. The transportation process is tracked from the beginning to the end. So, both parties can see any changes in the route.

Also, the parties can monitor any issues connected to the delivery and decide whose fault they were.

Blockchain technology innovates the logistics sector. The companies can simplify the delivery process, making routes shorter.

All these solutions lead to customer satisfaction. As a result, the clients trust companies and order goods or services more often.

The main advantage of blockchain is transparency. Business owners, as well as end consumers, have an opportunity to track the delivery process. Also, customers can ensure that during the delivery the storing conditions were followed.

However, developing blockchain-based solutions is an expensive and time-consuming process. Companies have to prepare beforehand and single out the requirements of the final product.

Link:
The Growing Role of Artificial Intelligence in the Pharmaceutical Industry - BBN Times

According to the latest study conducted by Trends Market Research (TMR) the global market for precision medicine is anticipate grow manifold, reflecting a robust CAGR of over XX% during 2018 to 2025.

Rapid augmentation of the medicine industry across the globe will certainly benefit the global market forprecision medicine. In addition, factors such as growing infrastructural development, higher investments, streamlined drug approval systems along with companion diagnostics are expected to favor the overall market growth during the assessment period. Cost-effective DNA profiling and increasing prevalence of carcinogenic diseases worldwide are additional factors that are projected to propel the market growth. Moreover, apt storage of genome data is of great significance to the global market for precision medicine as demand for data medicare is on the rise. However, acute data storage capacity, data privacy breach and discrepancies in funding systems and hefty price tag of personalized drugs may deter the market growth in the near future.

Enquiry More About This Report:https://www.trendsmarketresearch.com/report/sample/3437

The global market for precision medicine has been categorized into various parent segments that are further segmented into smaller sub-divisions.

On the basis of technology, next-gen sequencing, bioinformatics and drug discovery technology are expected to be the technologies highlighting the expanding the market width in forthcoming years. Based on applications, the oncology segment is expected to witness an overwhelming growth and is estimated to reach US$ XX Billion over 2025, reflecting a staggering XX% CAGR. This is primarily owing to increasing prevalence of tumor-related disease amongst the global geriatric population. On the other hand, increasing cases of arthritis will favor the growth of immunology segment, which is expected to surpass US$ XX Million in revenues by 2025 end.

Vendor News

Key players operating in the global market for precision medicine include Eli Lilly And Company, Novartis AG, AstraZeneca and Laboratory Corporation of America Holdings. Most of the companies are implementing market strategies involving mergers, tie-ups and acquisitions. Increasing collaboration between healthcare and IT is expected to deliver fruitful gains to the market, expanding the overall business canvas for the stakeholders in the upcoming years.

Request For Report Discounts @ https://www.trendsmarketresearch.com/report/discount/3437

The popularity of precision medicine has grown significantly across various parts of the world, hence on the basis of region, the markets for precision medicine in Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa (MEA) is set to achieve new figures of growth over the next eight years. Precisely, the market in North America is expected to present new lucrative opportunities, occupying over XX% share of the market during the forecast period. In addition, the region is estimated to surpass a market valuation of over US$ XX Million by the end of 2025.

The US and Canada will be the heavyweights of the global market owing to the existence of well-established medical industries in both the countries. In Europe, the market is expected to witness a steady growth and will increase its revenues charts close to US$ XX Million, riding on a healthy CAGR of over XX% during the assessment period. This is largely due to the increasing demand for precision medicines in countries such as France, UK, Italy and Germany. The Asia Pacific region is another region which is considered to be full of business potentials. The region is projected to increase at over XX% CAGR to reach approximately US$ XX Million by 2025 end. The market in APAC will be heavily dominated by Japan, while, India and China will compete for the second spot. Likewise, the in Latin America the market is expected to surge at a pace in terms of revenue over 2025. However, MEA will witness a sluggish growth of the market which is attributed to the lack of initiatives for conductive extensive research and development activities.

Make an Inquiry before [emailprotected] https://www.trendsmarketresearch.com/checkout/3437/Single

Visit link:
Precision Medicine Market to Witness a Healthy Growth during 2018-2025 - Curious Desk